Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 by Cha, J.-H. et al.
This is a repository copy of Metformin promotes antitumor immunity via 
endoplasmic-reticulum-associated degradation of PD-L1.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/152090/
Version: Accepted Version
Article:
Cha, J.-H., Yang, W.-H., Xia, W. et al. (25 more authors) (2018) Metformin promotes 
antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Molecular
Cell, 71 (4). 606-620.e7. ISSN 1097-2765 
https://doi.org/10.1016/j.molcel.2018.07.030
© 2018 Elsevier. This is an author produced version of a paper subsequently published in 
Molecular Cell. Uploaded in accordance with the publisher's self-archiving policy. Article 
available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/). 
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Metformin promotes antitumor immunity via endoplasmic 
reticulum-associated degradation of PD-L1
Jong-Ho Cha1,6,14, Wen-Hao Yang1,14, Weiya Xia1, Yongkun Wei1, Li-Chuan Chan1,7, Seung-
Oe Lim1, Chia-Wei Li1, Taewan Kim1, Shih-Shin Chang1, Heng-Huan Lee1, Jennifer L. 
Hsu1,8,9, Hung-Ling Wang8, Chu-Wei Kuo10, Wei-Chao Chang8,11, Sirwan Hadad12, Colin A. 
Purdie13, Aaron M. McCoy2, Shirong Cai2, Yizheng Tu2, Jennifer K. Litton3, Elizabeth A. 
Mittendorf4, Stacy L. Moulder3, William F Symmans5, Alastair M. Thompson4, Helen 
Piwnica-Worms2, Chung-Hsuan Chen11, Kay-Hooi Khoo10, Mien-Chie Hung1,7,8,9,15
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX 77030, USA
2Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX 77030, USA
3Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 
Houston, TX 77030, USA
4Department of Breast Surgical oncology, The University of Texas MD Anderson Cancer Center, 
Houston, TX 77030, USA
5Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 
77030, USA
6Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National 
University, Seoul 151-742, Korea
7Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, 
TX 77030, USA
8Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical 
University, Taichung 404, Taiwan
9Department of Biotechnology, Asia University, Taichung 413, Taiwan
Correspondence: Mien-Chie Hung. mhung@mdanderson.org.
Author Contributions
J.-H.C. and W.-H.Y. designed and performed the experiments, analyzed data, and wrote the manuscript; W.X., Y.W., L.-C.C, S.-O.L., 
C.-W.L., T.W.K., S.-S.C. and H.-H. L performed experiments and analyzed data; J.L.H. provided scientific input and wrote the 
manuscript; H.-L.W produced and characterized the PD-L1/S195-p antibody; C.-W. K and K.-H. K performed LC-MS/MS for glycan 
structure and analyzed data; W.-C.C. and C.-H. C. supported MS/IP and analyzed data; S.H., C.A.P., and A.M.T. provided metformin-
treated human breast tumor samples; A.M.M., S.C., Y.T., and H.P.-W. provided breast cancer PDX model; S L. M., W. F. S., J.K.L. 
and E.A.M. contributed human breast tumor tissues to establish PDX model; M.-C.H. supervised the entire project, designed the 
experiments, analyzed data, and wrote the manuscript.
Declaration of Interests
The authors declare no competing interests.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered 
which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Mol Cell. Author manuscript; available in PMC 2019 October 10.
Published in final edited form as:
Mol Cell. 2018 August 16; 71(4): 606–620.e7. doi:10.1016/j.molcel.2018.07.030.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
10Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan
11Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan
12Department of Surgery, University of Sheffield, Western Bank, Sheffield S10 2TN, UK
13Department of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
14These authors contributed equally
15Lead Contact
Summary
Metformin has been reported to possess antitumor activity and maintain high cytotoxic T 
lymphocyte (CTL) immune surveillance. However, the functions and detailed mechanisms of 
metformin’ s role in cancer immunity are not fully understood. Here we show metformin increases 
CTL activity by reducing the stability and membrane localization of programmed death ligand-1 
(PD-L1). Furthermore, we discover that AMP-activated protein kinase (AMPK) activated by 
metformin directly phosphorylates S195 of PD-L1. S195 phosphorylation induces abnormal PD-
L1 glycosylation, resulting in its ER accumulation and ER-associated degradation (ERAD). 
Consistently, tumor tissues from metformin-treated breast cancer patients exhibit reduced PD-L1 
levels with AMPK activation. Blocking the inhibitory signal of PD-L1 by metformin enhances 
CTL activity against cancer cells. Our findings identify a new regulatory mechanism of PD-L1 
expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade 
combination has the potential to increase the efficacy of immunotherapy.
eTOC blurb
Cha et al. elucidated a mechanism that metformin-activated AMPK phosphorylates PD-L1 at S195 
to induce abnormal glycosylation and degrades PD-L1 through ERAD pathway. This study 
suggests the potential to use metformin as an adjuvant with various non-PD-L1/PD-1 targeting 
immune therapies.
Graphical Abstract
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Introduction
Metformin is a widely used oral medication to treat type 2 diabetes (T2D) and recognized as 
a safe and well-tolerated drug from several decades of clinical experience. In addition, 
metformin has been reported to exert antitumor effects as several case-control studies of 
T2D patients showed metformin treatment reduced the incidence of various cancer types 
(Evans et al., 2005; Viollet et al., 2012). Moreover, metformin also maintains high cytotoxic 
T lymphocyte (CTL) activity in tumor tissues (Eikawa et al., 2015). Those findings imply 
that the antitumor effects of metformin may play a role in immune response against tumor 
progression.
During the process of immune editing, cancer cells cleverly escape immune surveillance by 
manipulating immune checkpoint molecules, which are critical to maintaining a balanced 
immune activity to prevent autoimmunity and limit collateral tissue damage (Watanabe and 
Nakajima, 2012). Programmed death ligand-1 (PD-L1) is a critical immune checkpoint 
molecule exploited by cancer cells to escape immune surveillance (Pardoll, 2012). When 
PD-L1 on cancer cells and macrophages binds to programmed cell death protein-1 (PD-1) 
on activated CTLs infiltrating into tumors, PD-L1-induced inhibitory signal shuts down their 
antitumor activity (Chen, 2004). Furthermore, PD-L1 is expressed at relatively much higher 
levels in tumor tissues compared with normal tissues (Topalian et al., 2016). Thus, blocking 
the PD-L1/PD-1 axis is recognized as the attractive target for cancer immunotherapy (Chen 
and Han, 2015).
Glycosylation is an important post-translational modification, which facilitates the folding 
(Shental-Bechor and Levy, 2008), intracellular transport (Vagin et al., 2009), and function of 
immunogenic glycoproteins (Wolfert and Boons, 2013). Specifically, N-glycosylation of 
PD-L1 was recently demonstrated to be essential for its function (Li et al., 2016). This type 
of modification is a stepwise reaction carried out from the endoplasmic reticulum (ER) to 
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the Golgi apparatus. Normally, the precursor glycan (Glc3Man9GlcNAc2) covalently 
attached to NXT motif (-Asn-X-Ser/Thr-) of glycoprotein is trimmed to Man8GlcNAc2 in 
the ER followed by glycan remodeling in the Golgi (Breitling and Aebi, 2013). However, 
when the protein is misfolded or when abnormal glycan structure is present, the ER  ?−1,2 
mannosidase I (ERMan I), ER degradation-enhancing  ?-mannosidase-like protein 1 
(EDEM1), EDEM2, and EDEM3 inordinately remove mannose from Man9GlcNAc2, 
resulting in Man7–5GlcNAc2 that is recognized by the ERAD complex (Ferris et al., 2014; 
Xu and Ng, 2015). The ERAD complex consists of various components for substrate 
recognition, ubiquitination, and retro-translocation (Xu and Ng, 2015). N-linked 
glycoproteins with abnormal Man7–5GlcNAc2 are recognized by the ERAD substrate 
recognition factors, OS-9 and ERLEC1, and ERAD E3 ligase, such as HRD1, is recruited to 
the substrate via the adaptor protein SEL1L (Vembar and Brodsky, 2008; Xu and Ng, 2015). 
Following poly-ubiquitination by SEL1L/HRD1, the substrate is retro-translocated from the 
ER into the cytoplasm and subsequently degraded by the cytoplasmic proteasome (Sun et 
al., 2015; van den Boomen and Lehner, 2015).
Previous diabetes studies indicated that the AMP-activated protein kinase (AMPK) is a main 
effector of metformin (Zhou et al., 2001), and that metformin may indirectly activate AMPK 
by inducing stress conditions, such as mitochondrial malfunction that depletes ATP (Hawley 
et al., 2010). AMPK is a heterotrimeric Ser/Thr kinase consisting of one catalytic ( ?) and 
two regulatory ( ? and  ?) subunits and functions as a key regulator of cellular metabolism 
and energy homeostasis (Hardie et al., 2016). Under various stress conditions consuming 
ATP, several upstream kinases activate AMPK via phosphorylation of Thr172 in the 
activation loop of its  ?subunit. In addition, AMPK is known to suppress tumor progression 
(Kuhajda, 2008), implying that the antitumor effect of metformin may be mediated by 
AMPK signaling.
The detailed molecular mechanism of metformin-mediated antitumor immunity is not well 
understood. Here we show that AMPK activated by metformin decreases the expression of 
PD-L1 in the cancer cells by altering PD-L1 glycan structure, which promotes PD-L1 
degradation, and subsequently blocking immune inhibitory signaling. We further evaluate 
the addition of metformin to boost the efficacy of immunotherapy as a potentially effective 
combination therapy for cancer treatment.
Results
Metformin increases CTL activity through the AMPK/PD-L1 axis
To investigate the role of metformin in antitumor immunity, we compared the antitumor 
effects of metformin between immunocompetent and severe combined immune deficiency 
(SCID) mice in a 4T1 breast tumor model (Figure 1A). Interestingly, significant tumor 
regression was only observed in immunocompetent mice but not those with immune 
deficiency after one week of metformin treatment (Figure 1B, C), suggesting that the 
antitumor effect of metformin is closely related to immune response. Because antitumor 
immunity is accompanied by apoptosis in tumor tissues (Chen et al., 2004), we compared 
the levels of cleaved caspase 3 (CCA3) and found that although a small number of cells 
underwent apoptosis in tumor tissues of the control mice, strong clustered apoptotic signals 
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were extensively observed in that of the metformin-treated group (Figure 1D). CD8+CTL, 
the major effector of antitumor immunity, eliminate cancer cells by secreting granzyme B 
(GB), an apoptosis trigger (Chowdhury and Lieberman, 2008). Thus, we examined the 
CD8+CTL population as well as CTL activity by measuring GB release and showed that 
metformin treatment indeed increased the CD8+ CTL population and GB release by 2.2 
(± 0.58) and 3.45 (± 0.81) fold, respectively, compared to control (Figure 1E). Together, 
these data suggested that metformin increases CTL activity, which may contribute to its 
antitumor effects.
Because AMPK is a major effector of metformin in diabetes (Zhou et al., 2001), we 
speculated that AMPK may also be involved in the increased T-cell activity induced by 
metformin. Thus, we performed T-cell killing assay using wild-type (WT) and AMPK 挀 
knockout (KO) MDA-MB-231 or AMPK ? knockdown (KD) BT-549 breast cancer cells 
(Figure 1F, S1A and S1B). Knocking out AMPK ? significantly neutralized metformin-
induced T cell-mediated cancer cell death compared with WT cells (Figure 1F and S1B; red 
highlight). Because cancer cells exploit immune checkpoints to inhibit CTL activity 
(Pardoll, 2012), we next investigated the association between AMPK ? and immune 
checkpoint proteins. To this end, we found that metformin treatment decreased the 
expression of PD-L1 among several major checkpoint proteins (Figure S1C). Therefore, we 
examined the expression and activity level of AMPK ? and PD-L1 in a panel of breast 
cancer cell lines and found they correlated negatively (Figure 1G and S1D). To further 
validate the association between metformin, AMPK ?, and PD-L1, we treated BT-549 and 
MDA-MB-231 cells with increasing concentrations of metformin. The expression of PD-L1 
was reduced with a clear band shift (red asterisk) in a dose- and time-dependent manner 
whereas the activated form of AMPK ? was increased (Figure 1H and S1E). Such reduction 
in PD-L1 by metformin was also demonstrated in non-small cell lung cancer (H1975 and 
H358) and colon cancer (RKO) cells (Figure S1F). The addition of a more specific AMPK 
activator, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), also decreased the 
levels of PD-L1 with a band shift (Figure S1G, red asterisk). Furthermore, when AMPK was 
pharmacologically and genetically inhibited, such reduction in PD-L1 expression was not 
observed (Figure 1I). Functionally, the reduction in PD-L1 expression on the membrane 
(Figure 1J) led to substantial decrease in PD-1 binding (Figure 1K). Knocking out PD-L1 in 
the MDA-MB-231 and BT-549 (PD-L1 KO) abrogated metformin-induced T cell-mediated 
cell killing compared with control (WT) cells (Figure 1L and S1H). Collectively, these 
results suggested that AMPK activated by metformin decreases PD-L1 levels in cancer cells, 
which in turn increases CTL activity against cancer cells.
AMPK activated by metformin directly phosphorylates serine 195 of PD-L1
To determine whether AMPK interacts directly with PD-L1, we performed a Duolink 
(Figure 2A and S2A) and co-immunoprecipitation (IP) assay (Figure 2B) with or without 
metformin. AMPK-PD-L1 binding peaked at 3 hr after metformin treatment and maintained 
for more than 24 hr. Consistently, GST pull-down assay showed that AMPK bound to PD-
L1 directly (Figure S2B). We also demonstrated that PD-L1 is a substrate of AMPK as 
AMPK directly phosphorylated PD-L1 by in vitro kinase assay (Figure 2C). The kinetic 
assay showed that the substrate affinity of PD-L1 to AMPK was higher than that of acetyl-
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CoA carboxylase (ACC), a known AMPK substrate (Fullerton et al., 2013) (Figure 2D). 
Based on the reported phospho-motif of AMPK (Hardie et al., 2016), S195 of PD-L1 was 
predicted as the phospho-site for AMPK (Figure S2C), which was also detected by mass 
spectrometric analysis (Table S1). Alanine mutation of PD-L1 S195 (S195A; non-
phosphorylated form) abrogated its phosphorylation by AMPK (Figure 2E). To further 
support the existence of PD-L1 S195 phosphorylation (S195-p) in vivo, we generated a 
specific antibody against PD-L1 S195-p (Figure S2D). Interestingly, to detect S195-p, it was 
necessary to remove the glycan structure by PNGase F after IP purification (Figure S2E), 
indicating that the glycan structures near S195 interfered with the binding of the PD-L1 
S195-p antibody. Phosphorylation of S195 of wild-type (WT) PD-L1 increased at 2 hr after 
metformin treatment and peaked around 6 hr. In contrast, no phosphorylation was observed 
in the S195A mutant (Figure 2F), and knocking out AMPK ? abolished S195-p of PD-L1 
(Figure 2G).
Since Ser 195 is present on the extracellular domain (ECD), its phosphorylation by AMPK 
should occur in the ER or/and Golgi lumen. PD-L1 is located in the ER, Golgi, cytoplasmic 
membrane, and nucleus (Satelli et al., 2016), and AMPK is known to be present in the ER, 
Golgi, cytoplasm and nucleus (Qi et al., 2008). Moreover, a recent study reported high 
AMPK activity in the ER and Golgi (Miyamoto et al., 2015). Consistently, cellular 
fractionation (Figure 2H) also indicated that AMPK is located in the ER region. To further 
determine whether AMPK resides in the ER lumen, we carried out trypsin digestion of the 
ER fractions with or without pre-permeabilization and then examined the levels of AMPK, 
ER transmembrane protein IRE1 挀 (cytosolic part), and ER lumen protein HSP90B1 using 
the indicated antibodies (Figure S2F). In the permeable fraction, no signals were detected 
with antibodies against both cytosolic and luminal proteins after trypsinization (Figure 2I, 
Triton X100 (+) and S2F, panel b). In the non-permeable fraction, signal for the cytosolic 
domain of IRE1 ? were rapidly reduced after trypsinization, whereas signals for AMPK and 
HSP90B1 were maintained (Figure 2I, Triton X100 (−) and S2F, panel c). These results 
strongly supported localization of AMPK inside the ER lumen.
Data from Duolink® assay indicated that the binding between PD-L1 and AMPK (Duo: red) 
occurred in the ER (HSP90B1; green), Golgi (TNG46; magenta), and nucleus (Hoechst; 
blue) (Figure 2J). To further validate the binding between PD-L1 and AMPK on the luminal 
side, we performed Duolink assay (AMPK/PD-L1) with antibodies specific for ECD 
(86744S and ab205921) and the intracellular domain (ICD) (13684S and GTX104763) of 
PD-L1. Prior to detection of PD-L1/AMPK interaction by Duolink assay, these four 
antibodies were first verified for IF staining (Figure S2G) as control in parental BT-549 and 
PD-L1 KO BT-549 cells. Our results indicated that the antibodies against ECD, but not those 
against ICD, exhibited strong Duolink signals (Figure 2K) which are co-localized with ER 
lumen marker HSP90B1 (Figure S2H; white arrow), suggesting that PD-L1 binds to AMPK 
primarily on the luminal side of ER (Figure S2I). Together, these results indicated that 
metformin-activated AMPK locates in the lumen of ER and directly phosphorylates PD-L1 
S195.
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Phosphorylation of PD-L1 S195 induces its abnormal glycosylation and blocks its ER-to-
Golgi translocation
To validate the function of S195-p, we generated BT-549 and MDA-MB-231 stable cell lines 
expressing WT, S195A (non-phosphomimetic), S195D (phosphomimetic), or S195E 
(phosphomimetic) PD-L1. To exclude endogenous signals from PD-L1, we knocked down 
endogenous PD-L1 in these stable cell lines (Figure S3A, Left). Interestingly, while bands of 
similar size representing WT and S195A PD-L1 were detected, the S195E and S195D 
mutant showed a significant band shift (Figure 3A and S3A, Right_red asterisk) similar to 
that in the presence of metformin (Figure 1H and S1E_red asterisk). PD-L1 contains four N-
glycosylation sites, N35, N192, N200, and N219 (Li et al., 2016) (Figure 3B), and is heavily 
glycosylated (Figure 3A, WT PD-L1 vs 4NQ PD-L1_non-glycosylated form). Based on the 
reduction in size, this band shifting may be attributed to the changes in the glycan structure. 
Indeed, when cells were treated with glycosylation inhibitor, tunicamycin, protein bands 
corresponding to WT, S195A, S195D, and S195E PD-L1 shifted down to a size similar to 
the non-glycosylated form (4NQ; red arrow), and none of the bands was below the size of 
4NQ (Figure. 3D). These results indicated that the difference in molecular weight between 
S195D and S195E PD-L1, and WT and S195A PD-L1 was due to alterations in the glycan 
structure. To validate this, we performed mass spectrometric analyses and showed that the 
glycan structure of the S195E mutant PD-L1 was different from that of WT PD-L1. Diverse 
glycan structures consisting of various saccharides, e.g., fucose, galactose, N-
acetylneuraminic acid, and N-acetylglucosamine, can be found on the WT PD-L1, but only 
the mannose-rich structures (M5, M6, M7, M8 and M9) were detected at the four 
glycosylation sites on S195E (Figure 3C, S3B and Table S2). Such mannose-rich structures 
are attributed to excessive ER mannose trimming (Ferris et al., 2014; Xu and Ng, 2015), and 
S195-p is expected to occur before ER trimming. Metformin treatment caused a band shift 
of WT PD-L1, but not S195A, to a size similar to that of the S195E mutant (red asterisk) 
(Figure 3D). These results suggested that metformin-activated AMPK directly 
phosphorylates PD-L1 at S195, which induces abnormal ER mannose trimming during 
glycosylation.
During intracellular transport of membrane glycoproteins, specific glycosylation in one 
compartment is closely related to the cargo transfer to the next (Vagin et al., 2009). Since 
S195-p induces abnormal glycosylation of PD-L1, we asked whether S195-p by metformin 
affects localization of PD-L1 in the cells. To this end, we performed IF staining of WT, 
S195A and S195E PD-L1 stable cell lines. Both WT and S195A PD-L1 were located 
primarily on the cell membrane (white arrowheads) and within the perinuclear cisternae (red 
arrowheads) (Figure 3E; see Figure 3F, G for more details). In contrast, S195E PD-L1 was 
detected throughout the cytosol with reduced signals on the membrane (Figure 3E; yellow 
arrow). Co-staining of PD-L1 (white; 1 and 5) and three Golgi markers (2 and 6), GM130 
(cis; blue), giantin (medial; green), and TNG46 (trans; magenta), showed that WT (3 and 4) 
but not S195E (7 and 8) PD-L1 colocalized with the Golgi markers (Figure. 3F). In contrast, 
co-staining of PD-L1 (red; 1 and 5) and the ER marker HSP90B1 (green; 2 and 6) indicated 
that S195E (7 and 8) but not WT (3 and 4) PD-L1 co-localized with the ER (Figure 3G). 
These data suggested that S195-p induces ER accumulation of PD-L1 by blocking ER-to-
Golgi translocation. Flow cytometric analysis also showed significantly lower cell 
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membrane PD-L1 in S195E than in WT or S195A (Figure 3H) PD-L1, which led to 
decreased binding with PD-1 (Figure 3I).
We next mutated the NXT motif to determine the glycosylation sites of PD-L1 affected by 
S195-p (Figure S3C). Individual PD-L1 mutations (N35Q, N192Q, N200Q and N219Q) did 
not affect subcellular localization of PD-L1 compared with the WT protein (Figure 3J, WT 
and NXT single mutants). In contrast, mutation at all four sites exhibited the same ER 
accumulation as did the S195E mutant (Figure 3J, 4NQ and S195E), implying that only 
severe abnormality in the collective glycan structure from S195-p leads to ER accumulation 
of PD-L1.
To validate the role of PD-L1 S195-p on the antitumor effect of metformin, stable cells 
expressing WT, S195A, or S195E PD-L1 were treated with metformin and assayed to 
examine PD-L1 localization (Figure S3D) and its activity in T-cell inhibition (Figure S3E, 
S3F and S3G). In the presence of metformin, WT PD-L1 accumulated in the ER similar to 
that observed for the S195E mutant (Figure S3D, WT and WT + Metf). ER localization of 
the S195A mutant, however, was not affected by metformin as shown by IF staining (Figure 
S3D, S195A and S195A + Metf). Functionally, the S195E PD-L1 stable cells induced higher 
T cell-mediated cytolytic activity compared with those expressing WT or S195A PD-L1 
(Figure S3E, S3F and S3G). Although metformin increased T cell-mediated killing of both 
WT and S195A stable cells, the reduction in cell survival of S195A stable cells was 
relatively less than that of WT PD-L1 (Figure S3F and S3G, red bars). Together, these data 
suggested that S195-P by metformin prevents the translocation of PD-L1 to the cell 
membrane and subsequent PD-1 binding, and therefore, increasing the activity of CTL.
Phosphorylation of S195 induces ER-associated degradation of PD-L1
The above findings indicated that PD-L1 S195-p induces a mannose-rich glycan structure 
and ER accumulation (Figure 3), which are common characteristics of ERAD substrates 
(Ferris et al., 2014; Vembar and Brodsky, 2008). We compared the binding partners of 
S195A and S195E PD-L1 by immunoprecipitation/mass spectrometry (IP-MS) analysis and 
found that eight of the top 10 candidates with increased binding to S195E were ERAD 
components (Figure 4A). Ingenuity pathway analysis based on this mass data showed the 
binding of PD-L1 with components of unfolding protein response (UPR) and ubiquitination 
pathway was increased by S195-p (Figure 4B). In addition, although the exogenous PD-L1 
protein level driven by the CMV promoter was decreased by metformin (Figure S4A), the 
endogenous RNA level of PD-L1 was not significantly changed (Figure S4B). These results 
strongly suggested that the reduction in PD-L1 level via metformin-induced S195-p is 
associated with the ERAD pathway.
As expected, S195E was less stable than WT or S195A PD-L1, and the stability of S195E 
was similar to that of the non-glycosylated 4NQ mutant (Figure 4C and S4C). Consistently, 
treatment of metformin or AICAR significantly reduced the stability of endogenous PD-L1 
(Figure S4D). Indeed, inhibition of the ERAD pathway by MG132 or eeyarestatin I (Eer I) 
restored S195E protein level (Figure 4D). Metformin treatment induced the binding of 
endogenous PD-L1 to the ERAD components, SEL1L, HRD1, ERLEC1, and OS9 (Figure 
4E, lines 2 vs 3). Yet, the phosphorylation-mimicking S195E PD-L1 bound strongly to these 
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ERAD components independently of metformin treatment (Figure 4F, lines 7 and 8). 
Metformin also increased the binding of WT PD-L1 (Figure 4F, lines 3 vs. 4), but not the 
S195A mutant (Figure 4F, lines 5 vs. 6), to ERAD components. Since ERAD is 
accompanied by poly-ubiquitination (Lemus and Goder, 2014), we also examined the 
changes in ubiquitination of PD-L1 by metformin. Ubiquitination of endogenous PD-L1 was 
substantially increased after metformin treatment (Figure 4G, lines 2 vs 3). Without 
metformin, the S195E mutant was highly ubiquitinated compared with WT PD-L1 (Figure 
4H, line 2 vs. 4). In the presence of metformin, WT PD-L1 exhibited similar ubiquitination 
to S195E (Figure 4H, line 6 vs. 8) whereas no changes were observed for the S195A mutant 
(Figure 4H, line 3 vs. 7). When the K48R mutant ubiquitin (non-polymerized form) was 
used for assay, no changes in ubiquitination were observed (Figure S4E) for all three forms 
of PD-L1, indicating that increased ubiquitination of PD-L1 is poly-ubiquitination 
associated with proteasomal degradation. Since the ERAD E3 ligase HRD1 (Ferris et al., 
2014) bound to PD-L1, we examined the possibility that HRD1 also functions as an E3 
ligase of PD-L1. Knocking down HRD1 clearly reduced the ubiquitination of endogenous 
PD-L1 (Figure 4I, lines 2 and 3 vs. 4 and 5) induced by metformin and abrogated the strong 
ubiquitination of the S195E mutant (Figure 4J, lines 2 and 3 vs. 5 and 6). Consistently, 
knocking down HRD1 increased the stability of PD-L1 S195E and 4NQ mutants, suggesting 
that HRD1 functions as an E3 ligase during ERAD of PD-L1 (Figure S4F). Finally, 
knocking down the ERAD components induced the accumulation of both endogenous PD-
L1 (Figure 4K, blue arrow, normal glycosylated; red arrow, abnormal glycosylated form) 
and S195E PD-L1 (Figure 4L). These data suggested that metformin-induced S195 
phosphorylation of PD-L1 promotes its degradation via the ERAD pathway.
The reduction of PD-L1 by metformin-activated AMPK is physiologically significant and 
clinically relevant
To validate these results that metformin reduces PD-L1 level via S195 phosphorylation in 
vivo, we generated mouse 4T1 stable cell lines expressing WT and human S195-equivalent 
mutants, S194A, or S194E PD-L1 as Ser194 of mouse (m) corresponds to Ser 195 of human 
(h) PD-L1 based on sequence homology analysis (Figure S5A). A band shift (Figure S5B) 
and ER accumulation (Figure S5C) similar to S195E hPD-L1 was also observed for S194E 
mPD-L1. Tumor growth of S194E mPD-L1 4T1 stable cells was significantly reduced 
compared to those expressing WT mPD-L1 in an immunocompetent mouse model (Figure 
5A). Furthermore, the antitumor effect of metformin was lower on S194A mPD-L1 than on 
WT mPD-L1 4T1 stable cells (Figure 5B and C). Consistently, S194E mPD-L1 4T1 tumors 
exhibited a significant increase in the CD8+ CTL populations and their activity compared 
with WT mPD-L1 4T1 tumors (Figure 5D, S195E + PBS and WT + PBS). Although 
metformin highly improved the CTL immunity in WT mPD-L1 4T1 tumors (Figure 5D, WT 
+ PBS and WT + Metf), such effects were relatively lower in S194A mPD-L1 4T1 tumors 
(Figure 5D, S195A + PBS and S195A + Metf). These data strongly support the notion that 
PD-L1 S195 phosphorylation is an important event for the antitumor effect of metformin.
To validate the above findings that metformin reduces PD-L1 level in human tumor tissues, 
we analyzed the association of AMPK ? T172-p and PD-L1 levels in tumor tissues from 
breast cancer patients treated with metformin (Hadad et al., 2015). Tumor tissues were 
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collected by needle biopsy before and after metformin treatment (see Methods) and analyzed 
in pairs (before and after). Among 17 patients, seven who showed elevated levels of 
AMPK ? T172-p after metformin treatment were considered to be responders. Six of the 
seven responders had decreased PD-L1 levels after metformin treatment (Figure. 5E, cases 
1~7; Fig. 5F, G). In contrast, the other ten non-responders did not show a clear correlation 
between AMPK ? T172-p and PD-L1 levels (Figure 5E_case 8~17). The strong negative 
correlation in responders is in agreement with our hypothesis that AMPK activated by 
metformin induces PD-L1 degradation via ERAD pathway. We also observed a negative 
correlation between AMPK ? T172-p and PDL1 in breast cancer PDX mouse model (Figure 
5H and I). A pair of SCID mice with the same patient tumor was treated with PBS or 
metformin. Seven days after metformin treatment, the levels of AMPK ? T172-p and PD-L1 
in the tumors were examined by IF staining and Western blotting. Metformin increased 
AMPK ? T172-p and reduced PD-L1 expression (Fig. 5H and I). These results suggested 
that the reduction of PD-L1 by metformin is physiologically significant and clinically 
relevant.
The combination of metformin and CTLA4 blockade effectively suppresses tumor growth 
in vivo
PD-L1 and CTLA4 immune inhibitory checkpoints function by different mechanisms, and 
recent studies have attempted to block both pathways to improve efficacy (Callahan et al., 
2014; Curran et al., 2010). Because we show that metformin blocks PD-L1/PD-1 signaling 
in the current study, we selected CTLA4 blockade for combination therapy with metformin 
in mouse 4T1 breast tumor model. Mice were treated with metformin and CTLA4 antibody 
as indicated (see Methods). Metformin treatment by both intraperitoneal injection and oral 
gavage reduced tumor size (Figure 6A, B and S6A) and increased survival rate (Figure 6C) 
similar to anti-CTLA4. Consistent with the above mechanistic findings, IF and flow 
cytometric analysis of tumor tissues showed that metformin reduced PD-L1 levels (Figure 
6D, E) and increased the CD8+CTL population and their activity (Figure 6D, F and S6B). 
Regarding T-cell activation, the effects of metformin as indicated by the levels of GB or 
IFN- ? appeared to be similar to or better than that of CTLA4 blockade (Figure 6D, F). In 
addition, the metformin and anti-CTLA4 combination demonstrated significant 
improvement in tumor burden, survival rate, and CTL activity (Figure 6A–F and S6A) with 
no significant changes in body weight or detectable toxicity in the kidney and liver (Figure 
S6C). Similar results from the combination treatment were also observed in B16F10 
melanoma (Figure 6G) and CT26 colon cancer (Figure 6H, I) immunocompetent mouse 
models. These findings suggested that metformin has the potential to enhance the efficacy of 
anti-CTLA4 therapy without additional toxicity.
Discussion
Metformin has been shown to directly induce antitumor effects by inhibiting the PI3K-Akt-
mTOR and Ras-MAPK signaling pathways critical for cancer progression or indirectly by 
systemically reducing glucose and insulin metabolism to attenuate cancer cell growth 
(Hajjar et al., 2013; Pernicova and Korbonits, 2014). In addition, studies more recently 
showed that metformin regulates the differentiation and activity of T cells through an 
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intrinsic pathway (Eikawa et al., 2015; Zhao et al., 2015), suggesting that the antitumor 
effects of metformin may also be linked to immune response. Here, our results further 
reinforced this possibility by demonstrating a new regulatory mechanism of PD-L1 
expression.
We identified S195-p of PD-L1 as a critical event that determines whether it is transported to 
the membrane or degraded by ERAD. In addition, we identified HRD1 as an ERAD E3 
ligase of PD-L1 (Figure 4I, 4J and S4F), implying that SEL1/HRD1, known to have a 
central role in ER quality control (van den Boomen and Lehner, 2015), may have important 
functions in anti-tumor immunity by regulating immune checkpoints. However, there are 
several possibilities how S195-p induces ERAD of PD-L1. First, the conformational changes 
induced by S195-p may mimic the unfolded form or simply facilitate the binding with 
ERAD complex. Second, ER accumulation due to malfunction during transfer to Golgi can 
turn on the ERAD pathway (Nishikawa et al., 1994), and S195-p may block access of PD-L1 
to the ER-to-Golgi transport system, such as the COPII complex (Zanetti et al., 2011). Third, 
the structural changes induced by S195-p can increase the affinity of PD-L1 to the factors 
related to ER glycan trimming, e.g., ERMan I or EDEMs. Indeed, overexpression of ERMan 
I or EDEMs has been reported to increase the degradation of ERAD substrates with 
excessive glycan trimming in cells (Xu and Ng, 2015). Moreover, high levels of ERMan I 
produces more mannose 5, 6, 7 glycan structures through excessive trimming (Ferris et al., 
2014), suggesting that increased encounters with these trimming factors can lead to 
abnormal glycan structures recognized by ERAD. Future studies are warranted to validate 
these hypotheses.
Consistent with previous studies reported the localization and kinase activity of AMPK to 
the ER and Golgi (Miyamoto et al., 2015; Qi et al., 2008), our data showed that AMPK, 
which phosphorylates S195 of PD-L1, was located in both the ER and Golgi, and the 
binding between AMPK and PD-L1 was detected in those compartments as well (Figure 2H 
and 2J). However, S195E PD-L1 (phosphorylation mimic form) was primarily detected in 
the ER but not Golgi (Figure 3F and 3G). Moreover, abnormal glycan trimming (Figure. 3C) 
and ERAD (Figure 4) of PD-L1 induced by S195-p occur in the ER prior to transport to 
Golgi. These results suggest that S195-p can take place before glycan trimming in the ER. 
Importantly, S195 is located in ECD of PD-L1, known to be exposed to lumen of ER and 
Golgi, not to the cytosol during transport. Moreover, the ER trypsinization assay clearly 
showed that AMPK practically locates in the lumen of ER (Figure 2I and S2F) and the 
advanced duo-link assay indicated that that PD-L1 binds to AMPK primarily on the luminal 
side of ER (Figure 2K, S2H and S2I). Together with these clear evidences, most reasonable 
interpretation is that AMPK can directly phosphorylate S195 of PD-L1 in the ER lumen. 
Further study is needed to explain how metformin-activated AMPK is located in the ER 
lumen.
Interestingly, the effects of metformin on tumor burden and CTL activity were much lower 
in S194A mPD-L1 than in WT mPD-L1 tumors, but the effects were not completely blocked 
(Figure 5B, 5C and 5D). Consistently, T cell-mediated cancer cell killing indicated that 
increased killing effect by metformin was significantly decreased in AMPK ? KO cells 
(Figure 1F and S1B) and S195A PD-L1 stable cells (Figure S3F and S3G), but not 
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completely neutralized, suggesting that metformin enhances T cell activity by not only 
blocking the inhibitory signal from cancer cells but also stimulating intrinsic T cell 
activation. A recent study indicated that metformin improves immune surveillance by 
reducing tumor hypoxia (Scharping et al., 2017). Consistent with those findings, we showed 
that metformin can enhance antitumor immunity by many approaches. The multiple 
functions of metformin may explain why it highly activates T cells similar to CTLA4 
immunotherapy (Figure 6).
Several clinical studies indicated that metformin exhibits substantial antitumor effects in 
breast cancer patients, suggesting its therapeutic potential (Camacho et al., 2015). Recently, 
increased activation of AMPK through phosphorylation at T172 was reported in tumor 
tissues from non-diabetic breast cancer patients who received metformin treatment (Hadad 
et al., 2015). Result from IHC staining of tumor tissues from metformin-treated breast 
cancer patients are in agreement with those clinical data (Hadad et al., 2015) and provide a 
mechanism by which metformin induces antitumor effects in breast cancer (Figure 5E, F and 
G). Control case study of breast cancer patients with diabetes showed that the pathological 
complete response rate after chemotherapy was higher in the metformin-treated group (24%) 
than in non-treated group (8%), implying that the prognosis after chemotherapy is improved 
by metformin (Hajjar et al., 2013). Because metformin blocks the PD-L1/PD-1 pathway 
(Figure. 1), chemotherapy for patients taking metformin can be considered a form of 
combined immunotherapy. Interestingly, tumor tissues from patients with triple-negative 
breast cancer, a breast cancer subtype that does not respond to targeted therapies due to the 
lack of estrogen receptor, progesterone receptor, and HER2 expression (Plasilova et al., 
2016), were found to have increased number of tumor-infiltrating lymphocytes accompanied 
by increased PD-L1 level (Wimberly et al., 2015). In this regard, metformin-mediated 
activation of CTL by blocking PD-L1/PD-1 signaling may be a potential treatment option 
for TNBC patients. Indeed, we showed that metformin can increase the killing effects of T 
cells in two TNBC cell lines, MDA-MB-231 and BT-549 (Figure. 1F, 1L, S1B, S3F, and 
S3G). Our data showed that metformin also reduced PD-L1 level in the non-small cell lung 
cancer (H1975 and H358) and colon cancer (RKO) cells (Figure S1F). In B16F10 melanoma 
and CT 26 colon cancer mouse models (Figure 6G, H, and I), metformin also led to 
improvement in tumor burden and survival rate. Future studies are warranted to extend 
current study to other cancer types.
Inhibitory immune checkpoint blockade by anti-CTLA-4, anti-PD-1, or anti-PD-L1 has 
provided substantial benefits to advanced cancer patients. Various approaches are under way 
to expand the benefits and improve the efficacy of these immune checkpoint inhibitors, 
including ongoing clinical trials to evaluate the combined blockade of CTLA4 and PD-L1 or 
PD-1 (Hassel, 2016; Wolchok et al., 2013). Another approach is combining immunotherapy 
with existing anticancer therapies like chemotherapy, radiation therapy, or targeted therapy 
(Bernstein et al., 2016; Parra et al., 2017). Despite these combinations having the potential 
to improve the outlook for cancer immunotherapy, they can also aggravate immune-related 
adverse events (irAEs) accompanied by checkpoint inhibition (Callahan et al., 2014; 
Champiat et al., 2016) or induce severe side effects with inherent toxicity of the anticancer 
therapies (Florento et al., 2012). In this regard, our findings indicated that metformin 
significantly improved the antitumor effects by CTLA4 blockade without detectable toxicity 
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(Figure 6 and S6) and suggested that metformin has strong potential to be used in 
combination with immunotherapy.
STAR Methods
Animal and toxicity studies
All animal experiments were performed in accordance with guidelines approved by MD 
Anderson’ s Institutional Animal Care and Use Committee. NOD SCID, BALB/c and 
C57BL/6 mice (6- to 8-week-old females) were purchased from Jackson Laboratories (Bar 
Harbor, ME, USA). Mouse 4T1-Luc2 (Figure 1B, C, D, and E; 5 × 104 cells, Figure. 5A, B, 
C, and D; 1 × 105 cells, Figure. 6A, B, C, D and Fig. S6; 1 × 105 cells), B16-F10 (5 × 104 
cells) or CT26 cells (1 × 105 cells) in 50 μL of medium mixed with 50 μL of matrigel 
basement membrane matrix (BD Biosciences, San Jose, CA, USA) were injected into the 
mammary fat pad (4T1) or subcutaneous tissue (B16F10 and CT26). Three (animal 
experiments in Figure 1) or four days (other animal experiments) after inoculation, 
metformin (200 mg/kg in 100 μL PBS) was administered to mice daily by i.p. injection for 2 
weeks (animal experiments in Figure 1) or until end point (other animal experiments). 
CTLA-4 antibody (100 μg/100 μL, Bio X Cell) or control hamster IgG (100 μg/100 μL, Bio 
X Cell) was administered to mice by i.p. injection on day 7, 10, and 13 after inoculation. 
Tumor size was measured as indicated in the figures, and tumor volume was calculated by 
using the formula:  ?/6 × length × width2. Tumor growth was quantified by bioluminescence 
imaging at end point. Mice received D-luciferin (2.5mg/100 μL; Sigma-Aldrich, St. Louis, 
MO, USA) via i.p. injection after anesthesia and were imaged using IVIS100 (Perkin Elmer, 
Waltham, MA, USA). Mice with tumors greater than 1,500 mm3 were sacrificed.
Blood (300 μl) was collected from the orbital sinus of mice using a microhematocrit blood 
tube at the end point of experiment. The blood was stored in the heparinized blood tube and 
subjected to biochemical analysis for liver marker enzymes alanine transaminase (ALT) and 
aspartate transaminase (AST) and kidney marker by-products creatinine and blood urea 
nitrogen (BUN) to evaluate treatment toxicity by COSBA INTERGRA 400 plus (Roche 
Diagnostics, Rotkreuz, Switzerland) at The Department of Veterinary Medicine and Surgery, 
The University of Texas MD Anderson Cancer Center.
Cell culture and treatment
All cell lines used were obtained from American Type Culture Collection (Manassas, VA, 
USA) and independently confirmed by STR DNA fingerprinting at Texas MD Anderson 
Cancer Center and tests for mycoplasma were negative. Human breast cancer cell lines and 
mouse cancer cell lines, were cultured in DMEM/F12, DMEM, MEM respectively, 
supplemented with 10% FBS and 1% antibiotic mixture. Human lung cancer cell lines and 
RKO were cultured in RPMI-1640, and MEM respectively, supplemented with 10% FBS 
and 1% antibiotic mixture. Metformin was added to complete medium at the indicated 
concentrations and times.
Cha et al. Page 13
Mol Cell. Author manuscript; available in PMC 2019 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Plasmids
The pGIPZ-sh PD-L1/Flag-hPD-L1 dual vector expressing Flag-PD-L1 with endogenous 
PD-L1 knockdown was constructed as described previously (Li et al., 2016). Briefly, 
pGIPZ-sh (h)PD-L1 clone #5 (3´-UTR region of (h)PD-L1: TTGACTCCATCTTTCTTCA, 
Thermo Scientific, Pittsburgh, PA, USA) and Flag-(h)PD-L1 WT (shRNA/ORF Core 
Facility UT MD Anderson Cancer Center, Houston, TX, USA) was constructed by the 
removal of GFP sequence in pGIPZ shPD-L1 clones #5 by Cla1 and Nhe1 restriction 
enzyme digestion and insertion of Flag-(h)PD-L1 WT. The pGIPZ-sh(h)PD-L1/Flag-PD-L1 
S195A, S195D and 4NQ were acquired through site–direct mutagenesis of the pGIPZ-
sh(h)PD-L1/Flag-PD-L1WT. pGIPZ-sh(m)PD-L1 clone #3 (Thermo Scientific, Pittsburgh, 
PA, USA) and Flag-(m)PD-L1 WT (shRNA/ORF Core Facility UT MD Anderson Cancer 
Center, Houston, TX, USA) were constructed for pGIPZ-sh(m)PD-L1/Flag-(m)PD-L1, 
which used as the template for pGIPZ-sh(m)PD-L1/Flag-(m)PD-L1 S194A and S194E. The 
pPET21a His-PD-L1 WT was constructed by inserting the extracellular domain (aa 19~238) 
of PD-L1 into pPET21a through Nde1 and Xho1 restriction enzyme digestion. The pPET21a 
His-PD-L1 S195A were acquired through site–direct mutagenesis of the pPET21a His-PD-
L1 WT. All plasmids were confirmed using enzyme digestion and DNA sequencing.
Generation of PD-L1 stable and knockout (KO) stable cells
Using a pGIPZ-shPD-L1/Flag-PD-L1 dual expression construct, we established MDA-
MB-231 and BT-549 stable cell lines expressing Flag-PD-L1 WT, S195A, S195E or 4NQ 
mutants with endogenous PD-L1 knockdown. Human PD-L1 KO MDA-MB-231 cells were 
generated using Pdcd-1L1 CRISPR/Cas9 KO vector (sc-401140, Santa Cruz, Dallas, TX, 
USA). To generate AMPK ? KO MDA-MB-231, three different regions of AMPK 挀 
1(NM_006251.5) and AMPK 挀 2 (NM_006252.3) were targeted using pLentiCRISPRv2 
vectors, respectively. The targeting sequences are as follows;
AMPK ?1–1 [CCAGGAACTGAGTCTGCGCA (−5 to −27);
AMPK ?1–2 [TGGCGCTATATACGCTGTTG (4008 to 4030);
AMPK ?1–3 [CATATTATTTGCGTGTACGA (1325 to 1347);
AMPK ?2–1 [AGAAGCAGAAGCACGACGGG (79 to 101);
AMPK ?2–2 [TACGTGCTGGGCGACACGCT (117 to 139);
AMPK ?2–3 [TCTTCAGTTTCACCTCGCCT (1647 to 1669).
To package lentivirus, the dual expression or LentiCRISPR KO constructs were transfected 
into HEK 293T cells with two packaging plasmids (VSV-G and delta 8.2). The medium was 
changed at 24 hr after transfection and supernatant collected twice with 24-hr intervals. The 
centrifuged supernatant was filtered using a 0.45-μm filter. MDA-MB-231 and BT-549 cells 
(30% confluency) were incubated in lentivirus-containing medium with polybrene (10 
μg/ml; EMD Millipore, Billerica, MA, USA). Forty-eight hr following infection, cells were 
subjected to puromycin selection (1 μg/ml; InvivoGen, San Diego, CA, USA).
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Transfection of siRNA and expressing vectors
Commercial siRNAs were used to knock down SEL1L (#1 SASI_Hs01_00233054 and #2 
SASI_Hs01_00233056; Sigma-Aldrich), ERLEC1 (#1 SASI_Hs02_00329444 and #2 
SASI_Hs02_00329447; Sigma-Aldrich), OS9 (#1 SASI_Hs01_00097558 and #2 
SASI_Hs01_00097559, Sigma-Aldrich) and HRD1 (SYVN1) (SignalSilence® SYVN1 
siRNA I #13204; Cell Signaling). siRNAs were transfected into MDA-MB-231 naïve cells 
and MDA-MB-231 PD-L1/S195E stable cells using Electroporator (Nucleofector II; Amaxa 
Biosystems) according to the manufacturer’ s instructions. pCMV HA-Ubiquitin (WT) and 
pCMV HA-Ubiquitin (K48R) were transfected into MDA-MB-231 PD-L1 WT, S195A, 
S195E, or mock stable cells with Lipofectamine® LTX with Plus™ Reagent (15338100; 
Life Technologies, Grand Island, NY, USA)
qRT–PCR assays
Cells were lysed with TRIzol (Life Technologies) immediately after washing with PBS. 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNA was 
synthesized from purified RNA using SuperScript III First-Strand cDNA synthesis system 
(Life Technologies) according to the manufacturer’ s instructions. qPCR was performed 
using real-time PCR machine (iQ5, BioRad). The comparative Ct method was used for the 
data analysis. HuPD-L1 mRNA were normalized to huGAPDH mRNA. The sequences of 
primers used for qRT PCR are as follows:
huPD-L1-F: 5´-ACAGCTGAATTGGTCATCCC-3´
huPD-L1-R: 5 ´-TGTCAGTGCTACACCAAGGC-3´
huGAPDH-F: 5´-AAGGTGAAGGTCGGAGTCAA-3´
huGAPDH-R: 5´-AATGAAGGGGTCATTGATGG-3´.
Identification of N-glycopeptides
The gel band containing either PD-L1WT or S195E was excised for in-gel trypsin digestion. 
The extracted peptide mixtures were then analyzed by nanospray LC-MS/MS on an Orbitrap 
Fusion Tribrid (Thermo Scientific, Waltham, MA, USA) coupled to an UltiMate 3000 
RSLCnano System (Dionex, Thermo Scientific). The detailed sample preparation 
procedures and parameters used for MS and MS/MS analysis have been described 
previously (Yagi et al., 2016). For N-glycopeptide identification, the raw data file was 
processed and analyzed directly by Byonic (v 2.7.4) and the resulting assignments were 
further examined manually.
Immunofluorescence
Under anesthesia, the tumor mass was isolated from mice after perfusion with 0.1 M PBS 
(pH 7.4) and embedded into OCT block and frozen for cryostat section. Cryostat sections (8-
μm thick) were fixed with 4% paraformaldehyde (PFA) for 15 min at room temperature 
(RT). After PBS washing, cryostat sections were incubated in the blocking solution (PBS 
including 3% donkey serum, 1% BSA, 0.3% Triton X-100, pH 7.4) for 30 min at RT. For 
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cell staining, cells on round cover glass were fixed in 4% PFA at RT for 15 min after PBS 
washing. Cells were permeabilized in 0.5% Triton X-100 for 10 min and then in the 
blocking solution for 30 min at RT. In antibody reaction buffer (PBS plus 1% BSA, 0.3% 
Triton X-100, pH 7.4), samples were stained with primary antibodies against active caspase 
3 (9661L, 1:300; Cell Signaling Technology, Danvers, MA, USA ), CD8 (MCA609G, 1:100; 
BioRad, Hercules, CA, USA), GranzymeB (AF1865, 1:500; R&D Systems, Minneapolis, 
MN, USA), PD-L1 (13684, 1:200; Cell Signaling Technology), HSP90B1 (NBP2–42379, 
1:300; Novus Biologicals, Littleton, CO, USA), GM130 (610823, 1:200; BD Biosciences, 
San Jose, CA, USA), Alexa fluor 488 Giantin (908701, 1:200; BioLegend, San Diego, CA, 
USA), TNG46 (NB110–62093, 1:400; Novus Biologicals) overnight at 4 °C, followed by 
Alexa 350, 488, 546, and 647 (1:3,000, Life Technologies) secondary antibodies at RT for 1 
hr. Hoechst 33342 (Life Technologies) was used for nuclear staining. To show the binding 
between AMPK ? and PD-L1 in vivo, primary antibodies for PD-L1 (338364, 1:200; LSBio, 
Seattle, WA, USA), PD-L1 (ab205921, 1:200; Abcam), PD-L1 (86744S, 1:200; Cell 
Signaling Technology), PD-L1 (13684S, 1:200; Cell Signaling Technology), PD-L1 
(GTX104763, 1:200; GeneTex), and AMPK 挀 (AF2850, 1:300; R&D Systems) were applied 
to duo-link assay (DUO92101; Sigma). The confocal microscope (LSM700; Carl Zeiss, 
Thornwood, NY, USA) were used for image analysis.
Western blotting and co-immunoprecipitation
For Western blot analysis, cells were lysed in lysis buffer (1.25M urea and 2.5% SDS) after 
PBS washing. The viscosity of the lysate was removed by sonication, and protein 
concentration measured by bicinchoninic acid (BCA) reaction. Immunoblotting was 
performed with primary antibodies against PD-L1 (13684, 1:1,500; Cell Signaling 
Technology), PD-L1 (338364, 1:1,000; LSBio), AMPK 挀 (5831S, 1:2,000; Cell Signaling 
Technology), AMPK ?1 (AF3197, 1:2000; R&D Systems), AMPK ?2 (AF2850, 1:2000; 
R&D Systems), AMPK ? Thr172-p (2535S, 1:1,000; Cell Signaling Technology), Flag-tag 
(14793S, 1:2,000; Cell Signaling Technology), SEL1L (S3699, 1:5,000; Sigma-Aldrich), 
HDR1 (14773S, 1:2000; Cell Signaling Technology), ERELC1 (ab181166, 1:3,000; Abcam, 
San Francisco, CA, USA), OS9 (12497S, 1:1,000; Cell Signaling Technology), HIS-tag 
(A00186, 1:5000; GenScript), GST-tag (A190–122A, 1:10000; Bethyl Lab), HA-tag (3724S, 
1:3,000; Cell Signaling Technology), GAPDH (2118, 1:3,000; Cell Signaling Technology), 
 ?-Tubulin (B-5–1-2, 1:5,000; Sigma-Aldrich),  ?-Actin (A2228, 1:10,000; Sigma-Aldrich). 
For Co-IP, cells were lysed in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, and 1 μg/ml leupeptin and protease inhibitor cocktail). 
Lysates (1 mg) were mixed with anti-PD-L1 (13684, 1:200; Cell Signaling Technology) or 
AMPK 挀 (5831S, 1:200; Cell Signaling Technology) overnight at 4 °C and then pulled-
down with protein G magnetic bead (9006, 1:30; Cell Signaling Technology) at 4 °C for 6 
hr. For Flag-IP, lysates (500 μg) were incubated with M2 magnetic bead (M8823, 1:25; 
Sigma-Aldrich) at 4 °C for 6 hr. The magnetic beads bound with target proteins were washed 
with same lysis buffer and eluted with 3X LSB sample buffer or through flag-peptide 
competition.
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GST pull-down assay
Commercial recombinant human GST (ab70456; Abcam), PD-L1/GST (ag12432; 
Proteintech), and AMPK holo complex (PV6238; Invitrogen) were subjected to GST pull-
down assay. The conjugation of GST and PD-L1/GST with glutathione beads and the pull-
down assay were performed using Pierce GST Protein Interaction Pull-Down Kit (21516; 
Thermo Scientific) according to manufacturer’ s instructions.
Antibody generation and detection
The anti-phospho-huPD-L1 Ser195 antibody was raised against the region near Ser195 
phosphorylation site of PD-L1. The phosphorylated synthetic peptide [C-
KKLFNVTS(p)TLRINK] was used for immunization in the mice. The antibody was 
generated as previously described (Li et al., 2016). For detection, PD-L1 protein was 
purified through immunoprecipitation as described above. All glycan structures on purified 
PD-L1 protein were removed by PNGase F (New England BioLabs, Ipswich, MA, USA) at 
37 °C for 1 hr and then the immunoblotting was performed with anti-phospho-huPD-L1 
Ser195 (1:500).
PD-L1 and PD-1 binding assay
To measure interaction between PD-1 and PD-L1 proteins, cells were fixed in 4% PFA at RT 
for 15 min and then incubated with recombinant human PD-1 Fc protein (R&D Systems) for 
1 hr, followed by anti-human Alexa Fluor 488 secondary antibodies (Life Technologies) at 
RT for 1 hr. Nuclei were stained with Hoechst 33342 (Life Technologies). The fluorescence 
intensity of Alexa Fluor 488 was measured with a microplate reader Synergy Neo (BioTeK, 
Winooski, VT, USA) and the cells were visualized using a confocal microscope (LSM700, 
Carl Zeiss).
T cell-mediated tumor cell killing assay
To acquire activated T cells, human peripheral blood mononuclear cells (PBMC; 
STEMCELL Technologies, Vancouver, BC, Canada) were cultured in ImmunoCult™-XF T 
cell expansion medium (10981; STEMCELL Technologies) with ImmunoCult™ Human 
CD3/CD28/CD2 T cell activator (10970; STEMCELL Technologies) and IL-2 (10 ng/mL; 
PeproTech, Rocky Hill, NJ, USA) for one week according to the manufacturer’ s protocol. 
The experiments were performed in DMEM/F12 medium with anti-CD3 antibody (100 
ng/ml; 16–0037; eBioscience, Thermo Scientific), IL-2 (10 ng/ml). Cancer cells were 
allowed to adhere to the plates overnight and then incubated for 48 hr with activated T cells 
in the presence or absence of metformin (5 mM). The ratios between cancer cells and 
activated cells (1:3, 1:5, and 1:10) were modified according to the purpose of each 
experiment (see Figure Legends). T cells and cell debris were removed by PBS wash, and 
living cancer cells were then quantified by a spectrometer at OD (570 nm) followed by 
crystal violet staining.
CTL profile analysis by FACS
Mouse Tumor Dissociation Kit (130–096-730, Miltenyl Biotec) and gentle MACS Octo 
Dissociator (130–096-427, Miltenyl Biotec) were used to digest the excised tumors from 
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mice. Percoll gradient assay (17–5445-01, GE Healthcare) was then performed to separate 
cancer cells and enriched leukocytes. After blocking with CD16/CD32 (40477, 1:50; 
BioLegend, San Diego, CA, USA) antibody, cancer cell fractions were stained using PD-L1-
APC (564715, 1:100; BD) antibody. Enriched leukocyte fractions were stained using CD3-
PreCP (100325, 1:20; BioLegend, San Diego, CA, USA), CD8-APC/Cy7 (100713, 1:200; 
BioLegend), and CD45-APC (103111, 1:100; BioLegend) antibodies. After fixation 
(421401, BioLegend) and permeabilization (421402, BioLegend), intracellular INF ? was 
stained using INF ?-Pacific Blue (505817, 1:20; BioLegend) antibody. Stained T cells were 
analyzed by BD FACSCanto II (BD Biosciences) cytometer. Data was processed by the 
FlowJo software.
In vitro kinase assay
Recombinant His-PD-L1 WT and His-PD-L1 S195A (Extracellular domain; amino acids 
19–238) were expressed in E-coli (BL21) by isopropyl  ?-D-1-thiogalactopyranoside (IPTG) 
induction and purified with Ni-NTA Superflow Agarose (Thermo Scientific) from bacterial 
lysates. Protein kinase assay was performed in a solution consisting of HEPES-Brij Buffer, 
active AMPK holoenzyme (10 ng; Thermo Scientific), 0.3 mM AMP, 0.2 mM ATP (with 0.5 
mCi/mL  ?−32P-ATP for radioactive assay), and/or 1 μg of protein substrate at 30 °C for 30 
min. The kinase reaction was stopped by heating at 100 °C for 5 min in LSB sample buffer, 
and samples were subjected to SDS–PAGE, Coomassie staining and autoradiography.
ADP-Glo kinase assay
ADP-Glo™ Kinase assay kit (V9101, Promega, Corporation, Madison, WI, USA) was used 
to measure kinetics of PD-L1 (ab12688, Abcam) phosphorylation by AMPK (PV6238, Life 
Technologies) through a luminescent ADP detection assay. The well-known substrate of 
AMPK, ACC (ab157829, Abcam) was performed in this assay as a positive control. The 
experiments were carried on according to the manufacturer’ s protocol. The values of Km 
and Vmax for AMPK were calculated using the Michaelis-Menten equation using the 
Graphpad Prism software.
Cell fractionation and endoplasmic reticulum enrichment
Cell fractionation kit (9038, Cell Signaling Technology, Danvers, MA, USA) was used to 
extract membrane, cytosolic and nuclear protein. Endoplasmic reticulum (ER) microsomal 
fractions were prepared by ER enrichment kit (NBP2–29482, Novus Biologicals, Littleton, 
CO). All experiments were performed according to per manufacturer’ s instruction. Protein 
concentration was determined using the BCA protein assay kit (23225, Thermo Scientific, 
Waltham, MA, USA). Proteins (30 μg) from each fraction was analyzed by Western blotting.
Trypsinization of endoplasmic reticulum microsomal fractions
ER microsomal fraction (300 μl) was collected from 0.4 g cell pellet by ER enrichment kit 
(NBP2–29482, Novus Biologicals, Littleton, CO). After pretreatment with or without 1% 
triton X100 for 3 min, trypsin/EDTA (0.625 g/L trypsin and 0.05 g/L EDTA in PBS) 
solution was added to each ER microsomal fraction (20 μl). Samples were mixed and 
incubated for the indicated time. After trypsinization, mixed samples were subjected to 
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Western blot analysis using primary antibodies against IRE1 挀 (3294, 1:2000; Cell Signaling 
Technology), HSP90B1 (NBP2–42379, 1:3000; Novus), and AMPK 挀 (5831S, 1:2000; Cell 
Signaling Technology).
Immunohistochemical staining of human breast tumor tissues
Human breast tumor tissue collection and study approval were described previously (Hadad 
et al., 2011). This trial (07/S1402/19) were approval by the Tayside Local Research Ethics 
Committee. Non-diabetic women with operable invasive breast cancer were recruited in this 
trial. The patient tumor tissues were collected by 14-gauge core needle biopsy before and 
after metformin treatment. The regimen of oral metformin treatment as following: 500 mg 
daily for one week, increased to 1 g twice daily for another week. Twenty-five pairs of 
tissues (before and after metformin treatment) were obtained as previously described (Hadad 
et al., 2011), and among those, 17 pairs were available for IHC staining and analysis. 
Immunohistochemical staining was performed as previously described (Li et al., 2016) using 
PD-L1 (205921, 1:150; Abcam) and AMPK ? Thr172-p (2535S, 1:30; Cell Signaling 
Technology) antibodies. Briefly, tissue specimens were incubated with antibodies and a 
biotin-conjugated secondary antibody and then mixed with an avidin-biotin-peroxidase 
complex. Amino-ethylcarbazole chromogen was used for visualization. According to the 
immunoreactive score method, the intensity of staining (protein expression) was ranked into 
one of four groups: high (score 3), medium (score 2), low (score 1), and negative (score 0).
PDX model
The PDX model was obtained from the Cazalot Breast Cancer Model Resource at MD 
Anderson Cancer Center. This resource was established, in part, through a generous gift 
from the Cazelot family. Fragments form same tumor mass were implanted into BALB/c 
SCID mice as a pair. Metformin (200 mg/kg) was administered via i.p. injection for 7 days 
which began when tumor size reached around 500 mm3. The dissected tumor tissues were 
prepared for lysis and cryosection.
Statistical analysis
Data of bar graphs represents as percentage or fold change relative to control or untreated 
groups with standard deviation of three independent experiments. SPSS (Ver. 20, SPSS, 
Chicago, IL) was used for statistical analyses. Student’ s t test was performed to compare two 
groups of independent samples. The correlation between AMPK ? and PD-L1 was analyzed 
using Pearson Chi-Square test and Mann-Whitney test. A P value < 0.05 was considered 
statistically significant.
Data and Software Availability
https://data.mendeley.com/datasets/g66zzcbvfx/draft?a=e6eae081–06f3–44f2–
96fc-2fb7fce63a37
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Metformin enhances antitumor CTL immunity by blocking PD-L1/PD-1 axis.
• Metformin-activated AMPK directly binds to and phosphorylates PD-L1 at 
S195.
• Abnormal PD-L1 glycosylation induced by pS195 leads to PD-L1 
degradation by ERAD.
• Combination therapy with metformin and anti-CTLA4 has a synergistic 
antitumor effect.
Cha et al. Page 23
Mol Cell. Author manuscript; available in PMC 2019 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Metformin increases CTL activity through the AMPK/PD-L1 axis.
(A) 4T1_luc2 cells were injected into mice (n = 6 mice per group) on day 0, and metformin 
administered as indicated. (B) Tumor volume was measured on the indicated time points. 
Data represent mean ± SD. (C) Quantification (top) of bioluminescence imaging. Bottom, 
endpoint images shown (D) Immunostaining of cleaved caspase 3 in the 4T1 tumor mass. 
Hoechst: nuclear counter staining (pseudo-color: green). Scale bar, 200 μm (inset, 50 μm). 
(E) Immunostaining of CD8 (CTL marker) and granzyme B (activity of T cell) in the 4T1 
tumor mass. Scale bar, 200 μm (inset, 50 μm). For (D) and (E), data represent mean ± SD. n 
= 12; 3 tissue slides per tumor, 4 mice per group. Unit = 466,038 μm2 in (D) and 262,144 
μm2 in (E). (F) T cell-mediated cancer cell killing assay. MDA-MB-231 WT and AMPK 挀 
KO cells co-cultured with activated T cell for 48 hr with or without metformin (5 mM) were 
subjected to crystal violet staining. MDA-MB-231 to T-cell ratio, 1:5. Data represent mean ± 
SD. n = 3. (G) Correlation analysis between PD-L1 and AMPK ? T172-p expression in 14 
breast cancer cell lines. (H) BT-549 and MDA-MB-231 were treated with increasing 
concentrations of metformin (1.25 to 5 mM) for 24 hr. (I) MDA-MB-231 parental, AMPK 挀 
WT and KO cells were treated with metformin (5 mM) for 24 hr. Compound C (Com C) 
AMPK inhibitor was pretreated 6 hr before metformin treatment. (J) Membrane PD-L1 
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expression by flow cytometric analysis after metformin (5 mM) treatment for 24 hr. (K) 
Right, quantitation of binding of green fluorescent-labeled PD-1/Fc on MDA-MB-231 
treated with or without metformin for 24 hr. Data represent mean ± SD. n = 3. Left, 
representative images shown. Scale bar, 100 μm. (L) MDA-MB-231 WT and PD-L1 KO 
cells co-cultured with activated T cells for 48 hr with or without metformin (5 mM) were 
subjected to crystal violet staining. MDA-MB-231 to T- cell ratio, 1:3.
*P, 0.01~0.05, **P, 0.001~0.01, #P, < 0.001, and NS, not significant, Student’ s t test.
Cha et al. Page 25
Mol Cell. Author manuscript; available in PMC 2019 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. AMPK activated by metformin directly phosphorylates serine 195 of PD-L1.
(A) BT-549 cells were treated with metformin (5 mM) for the indicated time. Detection of 
endogenous AMPK ? and PD-L1 binding (red dots) by Duolink II assay. Three different 
positions were randomly selected at each point, and the number of red dots were divided by 
the number of nuclei. Data represent mean ± SD. n = 3. *P, 0.01~0.05, **P, 0.001~0.01, and 
#P, < 0.001, Student’ s t test. Scale bar, 20 μm. Right, MDA-MB-231 WT, PD-L1 KO and 
AMPK ? KO cells were used as negative controls. Scale bar, 25 μm. (B) MDA-MB-231 cells 
were cultured for 6 hr with or without metformin (5 mM) and MG132 (10 μM). Endogenous 
PD-L1 and AMPK ? were immunoprecipitated and their binding was analyzed with 
immunoblotting. (C) In vitro kinase activity of AMPK toward PD-L1 with 32P-labeled ATP. 
(D) Kinetics of PD-L1 phosphorylation by AMPK. Acetyl-CoA carboxylase (ACC) was 
used as positive control. Km and Vmax were calculated using the Michaelis-Menten 
equation. (E) In vitro phosphorylation assay and phospho-tag gel shifting assay. W, PD-
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L1/WT. A, PD-L1/S195A. (F) PD-L1/S195 phosphorylation was examined using anti-
PDL1/S195-p antibody at different time points after metformin (5 mM) treatment. (G) 
Western blot analysis of MDA-MB-231 WT and AMPK ? KO cells after metformin 
treatment (5 mM) for 8 hr. Endogenous PD-L1 purified by IP was subjected to 
immunoblotting with PDL1 S195-p antibody after PNGase F reaction. (H) PD-L1 and 
AMPK subcellular localization of MDA-MB-231 WT and AMPK ? KO cells. (I) Trypsin 
digestion of ER fractions with or without permeabilization. (J, K) BT-549 cells were treated 
with metformin (5 mM) for 3 hr. (J) BT-549 cells were subjected to Duolink II assay 
combined with immunofluoresence staining using markers for ER (HSP90B1), Golgi 
(TNG46), and nuclei (Hoechst). Scale bar, 20 μm (inset, 10 μm). (K) Duolink assay with 
antibodies specific for ECD (Ab205921 and 86744S) and ICD (13684S and GTX104763) of 
PD-L1. Scale bar, 50 μm (inset, 25 μm). Red dots: AMPK-PD-L1 binding in (J) and (K).
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Figure 3. Phosphorylation of PD-L1 S195 induces its abnormal glycosylation and blocks its ER-
to-Golgi translocation.
(A) WT, S195A S195D, S195E, and 4NQ PD-L1 stable cells were treated with or without 
tunicamycin (5 μg/ml) for 24 hr. (B) Schematic diagram of PD-L1 showing the position of 
S195 and the 4 N-glycosylation sites. (C) Comparison of the glycan structure between WT 
and S195E PD-L1 by IP/Mass analysis. (D) BT-549 and MDA-MB-231 stable cells 
expressing WT, S195E, or S195A PD-L1 were treated with metformin (5 mM) for 24 hr. (E) 
Expression pattern of PD-L1 in MDA-MB-231 WT, S195A and S195E PD-L1 stable cells 
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by IF staining. (F) MDA-MB-231 stable cells co-stained with antibodies against PD-L1 and 
Golgi markers (GM130: cis, Giantin: medial, TNG46: trans). (G) IF staining with antibodies 
against PD-L1 and ER marker (HSP90B1) (H) Flow cytometric analysis of membrane PD-
L1 in MDA-MB-231 WT, S195A and S195E PD-L1 stable cells. Data represent mean ± SD. 
n = 3. (I) Binding of green fluorescent-labeled PD-1/Fc to MDA-MB-231 WT, S195A and 
S195E PD-L1 stable cells was quantified. Data represent mean ± SD. n = 3. (J) PD-L1 
localization in MDA-MB-231 expressing WT, S195E or NXT motif mutant (glycosylation 
site mutant) PD-L1 by IF staining. For experiments shown in (E), (F), (G) and (J), MG132 
(10 μM) was added 6 hr prior to fixation to prevent degradation of PD-L1. Hoechst: nuclear 
counter staining. Scale bar, 20 μm (inset, 10 μm). *P, 0.01~0.05, **P, 0.001~0.01, and #P, < 
0.001, Student’ s t test. NS, not significant.
Cha et al. Page 29
Mol Cell. Author manuscript; available in PMC 2019 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Phosphorylation of S195 induces ER-associated degradation of PD-L1
(A) IP-MS analysis showing candidates with increased binding to PD-L1 S195E compared 
to PD-L1 S195A. ERAD components are shown in red. (B) IPA based on the mass data from 
panel (A) showing unfolding protein response and ubiquitination pathways closely related to 
ERAD were activated (C) MDA-MB-231 stable cells were treated with 50 μM 
cycloheximide (CHX) for the indicated time. The band intensity was quantified by Image J 
analysis. Data represent mean ± SD. n = 3. **P, 0.001~0.01, and NS, not significant, 
Student’ s t test. (D) MDA-MB-231 stable cells were treated with proteasome inhibitor 
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MG132 (10 μM) and ERAD inhibitor eeyarestatins (Eer I, 20 μM) for the indicated time. (E, 
F) MDA-MB-231 cells were treated with or without metformin (5 mM) for 24 hr and 
MG132 (10 μM) for 6 hr. Endogenous PD-L1 (E) or Flag-tagged WT, S195A, or S195E PD-
L1 (F) was pulled down by the PD-L1 antibody (E) or Flag M2 magnetic bead (F), 
respectively, followed by Western blotting to detect ERAD components (SEL1L, HRD1, 
ERLEC1, and OS9). (G) MDA-MB-231 cells expressing exogenous HA-ubiquitin were 
cultured with or without metformin (5 mM) for 24 hr followed by MG132 (10 μM) for 6 hr. 
Ubiquitination of endogenous PD-L1 was examined by HA immunoblotting after IP with 
antibody against PD-L1. (H) Ubiquitination of WT, S195A, and S195E PD-L1 was 
examined by HA immunoblotting after IP with Flag M2 magnetic bead. (I) Control or 
HRD1 siRNA was transfected into MDA-MB-231 cells expressing exogenous HA-ubiquitin. 
Ubiquitination of endogenous PD-L1 in each transfectant was examined by HA 
immunoblotting after IP with PDL1 antibody. (J) Control or HRD1 siRNA was transfected 
into MDA-MB-231 WT and S195E PD-L1 stable cells expressing exogenous HA-ubiquitin. 
Ubiquitination of WT and S195E PD-L1 was examined by HA immunoblotting after IP with 
Flag M2 magnetic bead. (K) siRNA targeting SEL1L, HRD1, OS9 or ERLEC1 was 
transfected into MDA-MB-231 (L) Each siRNA for ERAD components was transfected into 
MDA-MB-231 S195E PD-L1 stable cells followed by immunoblotting with the indicated 
antibodies. M, mock. W, WT PD-L1. A, S195A PD-L1. E, S195E PD-L1.
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Figure 5. The reduction of PD-L1 by metformin-activated AMPK is physiologically significant 
and clinically relevant
(A) 4T1 WT or S194E mPD-L1 stable cells (5 × 104) were injected into BALB/c mice (n = 
7 mice per group) (B) 4T1 WT or S194A mPD-L1 stable cells (5 × 104) were injected into 
BALB/c mice (n = 7 mice per group) on day 0, and metformin (200 mg/kg) administered by 
i.p. injection starting at day 4 for 18 days. Tumor volume was measured on the indicated 
time points. Data represent mean ± SD. (C) The relative tumor volume (%) at the end point 
(day 22) of panel (B). (D) Left, representative images of immunostaining of CD8 and GB in 
the 4T1 tumor mass. Hoechst: counter staining. Right, CD8 and GB were quantified using 
Image J. Data represent mean ± SD. n = 12. Three tissue slides per tumor, 4 mice per group. 
Unit = 262,144 μm2. (E) AMPK ? T172-p and PD-L1 levels before and after 
metformintreatment in tumor tissues of breast cancer patients. −, score 0; +, score 1; ++, 
score 2; +++, score 3; ᗏ, up; ᗑ, down; X, no change. (F) Representative IHC images of the 
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cases shown in panel (E). Scale bar, 50 μm. (G) Plot of IHC scores of AMPK ? T172-p and 
PD-L1 expression levels in responders before and after metformin treatment. n = 7 (H) PBS 
and metformin were administered to a pair of SCID mice with same patient tumor for 7 
days. Immunostaining of AMPK ? T172-p and PD-L1 in the PDX tumor mass. 
Hoechst:counter staining. Scale bar, 200 μm. (I) Western blotting of lysates from PDX 
tumors in (H) with the indicated antibodies.
*P, 0.01~0.05, **P, 0.001~0.01, and #P, < 0.001, Student’ s t test.
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Figure 6. The combination of metformin and CTLA4 blockade effectively suppresses tumor 
growth in vivo
(A) Tumor growth of 4T1 cells in immunocompetent BALB/c mice treated with control, 
metformin, anti-CTLA4, or the combination. Data represent mean ± SD. n = 8 mice per 
group. (B) Quantification (top) of bioluminescence imaging (endpoint images shown). The 
maximum and minimum values were excluded for more accurate analysis. Data represent 
mean ± SD. n = 6 mice per group. (C) Survival of mice bearing 4T1-derived tumor 
following treatment with control, metformin, anti-CTLA4, or the combination. n = 8 mice 
per group, log-rank test. (D) Top, immunostaining of PD-L1, CD8, and GB in the 4T1 tumor 
mass. Hoechst: nuclear counter staining. Scale bar, 50 μm (inset, 200 μm). Bottom, 
quantification of PD-L1, CD8, and GB using Image J. Data represent mean ± SD. n = 12 (4 
mice per group). Three tissue slides per tumor. Unit = 182,047 μm2. (E) Cells were extracted 
from 4T1-tumors by Percoll density gradient centrifugation. PD-L1 levels on extracted cells 
were evaluated by FACS. Cells were gated based on the FSC (forward scattered light) vs. 
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SSC (side-scattered light). Membrane PD-L1 is shown as median fluorescence intensity 
(MFI). Data represent mean ± SD. n = 5 per group. (F) FACS analysis of CD45+CD3+CD8+ 
CTL activity as indicated by the activity intracellular IFN- ? in the leukocyte fractions from 
Percoll density gradient separation. Detailed gating information is shown in Figure S6B. 
Data represent mean ± SD. n = 7 per group. Two or three tumors were collected for one 
sample for the combination group. (G) Tumor growth of B16F10 melanoma cells in 
immunocompetent C57BL/6J mice treated with control, metformin, anti-CTLA4, or the 
combination. Data represent mean ± SD. n = 6 mice per group. (H) Tumor growth of CT26 
colorectal cancer cells in immunocompetent BALB/C mice treated with control, metformin, 
anti-CTLA4, or the combination. Data represent mean ± SD. n = 6 mice per group. (I) 
Survival rate of mice bearing CT26-derived tumor following treatment with control, 
metformin, anti-CTLA4, or the combination. n = 10 mice per group, log-rank test.
*P, 0.01~0.05, **P, 0.001~0.01, and #P, < 0.001, Student’ s t test.
Cha et al. Page 35
Mol Cell. Author manuscript; available in PMC 2019 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
